Latest Janssen Pharmaceutical Companies Stories
NEW BRUNSWICK, N.J., May 7, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced a first-of-its-kind partnership that enlists a third party to review requests made to the Janssen
LONDON, May 6, 2015 /PRNewswire/ -- First programme to evaluate dual HIV maintenance therapy with dolutegravir and rilpivirine ViiV Healthcare today announced
Presentations include late-breaking final results from the Phase 3 OPTIMIST trials and interim results from the Phase 2 IMPACT trial of simeprevir CORK, Ireland, April 8, 2015 /PRNewswire/
New Focus in Disease Prevention, Disease Interception, and the Microbiome to Propel Scientific Innovation RARITAN, N.J., Feb.
Ask Agency to require that biosimilars bear distinguishable names to enhance patient safety WASHINGTON, Jan.
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.